Indications for LEXETTE:
≥18yrs: Apply a thin layer to affected areas twice daily for up to 2 weeks; max 50g/week. Discontinue when control is achieved. Reevaluate if no improvement within 2 weeks. Treatment beyond 2 consecutive weeks: not recommended. Do not occlude.
<18yrs: not established.
Not for ophthalmic, oral, or intravaginal use. Avoid use near eyes, on face, groin, or axillae. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma. Treat infection if present or develop; discontinue until infection resolved. Discontinue if allergic contact dermatitis occurs. Flammable. Reevaluate periodically. Pregnancy. Nursing mothers: avoid direct infant exposure.
Application site pain, headache; local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, dermatitis, secondary infection, miliaria), Cushing's syndrome, glucosuria, HPA axis suppression (esp. in children).
Generic Drug Availability: